Technology ID
TAB-4920
Targeting a Second CD4-Binding Site with Innovative Engraftment Techniques
E-Numbers
E-103-2020-0
Lead Inventor
Sajadi, Mohammad
Lead IC
NIAID
Co-Inventors
Lusso, Paolo
Liu, Qingbo
ICs
NIAID
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Research Products
Antibodies
This innovative technology represents a significant advancement in the field of HIV-1 therapy and prevention. By targeting a second, quaternary CD4-binding site with the engraftment of the VRC03 FR3 loop, it enhances the potency of broadly neutralizing antibodies against HIV-1. Importantly, this approach also addresses issues of autoreactivity and extends the antibody's half-life in vivo. Unlike previous methods that relied on random mutagenesis or the structural modification of classic interactive sites, this technology offers a novel and more effective strategy for improving the efficacy of anti-HIV antibodies.
Commercial Applications
This technology has the potential for a wide range of applications in the field of HIV-1 therapy and prevention. It could lead to the development of more effective treatments for HIV-1 infection, particularly in cases where current therapies have proven less successful. Additionally, this technology could be used to enhance the efficacy of vaccines aimed at preventing HIV-1 infection. By improving the potency of broadly neutralizing antibodies, this approach could help to bolster the immune response against HIV-1 and provide longer-lasting protection. Furthermore, the ability to reduce autoreactivity and prolong the antibody's half-life in vivo could make this technology suitable for use in a variety of therapeutic and prophylactic settings. Overall, the potential applications of this technology are vast and could have a significant impact on the field of HIV-1 research and treatment.
Competitive Advantages
This technology offers several competitive advantages over existing approaches in the field of HIV-1 therapy and prevention. By specifically targeting a second, quaternary CD4-binding site with the engraftment of the VRC03 FR3 loop, it enhances the potency of broadly neutralizing antibodies against HIV-1. This targeted approach not only increases the effectiveness of the antibodies but also reduces the risk of autoreactivity, a common concern with previous methods. Additionally, the technology's ability to prolong the antibody's half-life in vivo provides a more sustained and durable immune response against HIV-1. Overall, these advantages position this technology as a promising and innovative strategy for advancing HIV-1 therapy and prevention efforts.
Licensing Contact: